

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Attorney Docket No.: **ISPH-0754**  
Inventors: **Monia and Wyatt**  
Serial No.: **Not Yet Assigned**  
Filing Date: **Herewith**  
Examiner: **Not Yet Assigned**  
Group Art Unit: **Not Yet Assigned**  
Title: **Antisense Modulation of Fibroblast  
Growth Factor Receptor 3 Expression**

"Express Mail" Label No. **EV331020025US**  
Date of Deposit **July 30, 2003**

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Commissioner for Patents, Mail Stop Sequence, P. O.  
Box 1450, Alexandria, VA 22313-1450.

By *Jane Massey Licata*  
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents  
Mail Stop Sequence  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below; or
- ( ) The fee of \$240.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- ( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/953,047, filed September 10, 2001 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: July 30, 2003

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0754	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Monia et al.	
		Filing Date Herewith	Group Not yet assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Avraham et al., Mapping of murine fibroblast growth factor receptors refines regions of homology between mouse and human chromosomes, <i>Genomics</i> , 1994, 21:656-658	
	AB	Jang et al., Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer, <i>Cancer Res.</i> , 2000, 60:4049-4052	
	AC	Johnston et al., Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus, <i>J. Biol. Chem.</i> , 1995, 270:30643-30650	
	AD	Kannan et al., FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models, <i>IUBMB Life</i> , 2000, 49:197-205	
	AE	Keegan et al., Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3, <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1991, 88:1095-1099	
	AF	Li et al., A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors, <i>Hum. Mol. Genet.</i> , 1999, 8:35-44	
	AG	Ozawa et al., Growth factors and their receptors in pancreatic cancer, <i>Teratog. Carcinog. Mutagen.</i> , 2001, 21:27-44	
	AH	Plowright et al., Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis, <i>Blood</i> , 2000, 95:992-998	
	AI	Powers et al., Fibroblast growth factors, their receptors and signaling, <i>Endocr. Relat. Cancer</i> , 2000, 7:165-197	
	AJ	Richelda et al., A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene, <i>Blood</i> , 1997, 90:4062-4070	

Form PTO-1449 Modified		Docket No. ISPH-0754	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Applicant Monia et al.	
		Filing Date Herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AK	Sibley et al., Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma, <i>Oncogene</i> , 2001, 20:686-691	
	AL	Su et al., Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism, <i>Nature</i> , 1997, 386:288-292	
	AM	Thompson et al., A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4, <i>Genomics</i> , 1991, 11:1133-1142	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified	Docket No. ISPH-0754	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Applicant Monia et al.	
	Filing Date Herewith	Group Not yet assigned

**U.S. PATENT DOCUMENTS**

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

**FOREIGN PATENT DOCUMENTS**

Examiner's Initial		Document No.	Date	Country	Translation YES NO	
	AO	WO 00/68424	11/16/2000	PCT	X	
	AP	WO 01/36632	5/25/2001	PCT	X	
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

**EXAMINER**

**DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. <b>ISPH-0754</b>	Serial No.
		Applicant <b>Monia and Wyatt</b>	
		Filing Date	Group
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BA	Database N_ Geneseq, Accession No. AAD34806, Mouse FGFR3 allele detecting antisense PCR primer. July 16, 2002	
	BB	Database N_ Geneseq, Accession No. AAQ27543 January 29, 1993	
	BC	Database N_ Geneseq, Accession No. AAA54587, Primer used for detecting mutant fibroblast growth factor receptor 3. April 11, 2001	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	